Novartis has co-led a $17m series A round for Inflazome, which is working on treatments for a range of chronic inflammatory diseases.

Existing backer Bayer will invest $35m through a private placement alongside an initial public offering in which the gene editing company is initially looking to raise $90m.

Novartis has co-led a $17m series A round for Inflazome, which is working on treatments for a range of chronic inflammatory diseases.

The acquisition of Wayne State University spinout RetroSense followed a licensing agreement with University of California, San Diego for another compound and may yet exceed $60m.

The Medtronic and Bausch & Lomb-backed eye care medical device maker has raised $66m in a KKR-led round that took its total funding to more than $215m.

HaloDoc, backed by corporates Go-Jek and Blibli, operates an online platform that connects patients to licensed doctors, medical lab services and partner pharmacies.

Novo and others are set to reinvest in Apollo Endosurgery after it agreed to acquire Nasdaq-listed Lpath in a deal that will speed up its progress towards an initial public offering.